Apple Analyst Sees $840 Ahead and 4 Analyst Insights Making Rounds

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): According to Baird, any weakness before BioMarin’s R&D day should be a buying opportunity. The firm still thinks that the shares will trade on revenue expectations; however, talk of raised R&D expenses may possibly pressure on the shares. BioMarin has an Outperform rating and a $54 price target.

Apple Inc. (NASDAQ:AAPL): Supply constraints on iPhone 5 continue to ease, but now, supplies of the iPad mini seem to be tight, according to Sterne Agee. However, the firm increased its estimates on Apple, and and it has decided to keep a Buy rating and an $840 price target on the stock.

Our 20-page proprietary analysis of Apple’s stock is ready. Click here and to get your Cheat Sheet report now!

Polypore International Inc. (NYSE:PPO) Q4 estimate was reduced by Capstone to 50c from 52c because of weaker than expected Volt sales. The firm keeps its Buy ratings and $49 price target on the stock.

Skyworks Solutions Inc. (NASDAQ:SWKS): After the firm met with Skyworks’ CFO, Sterne Agee has gained confidence in Skyworks’ positioning with its two top customers. The firm is convinced that the company has experienced benefits from the rising sales of Samsung’s Galaxy S III, and it keeps its Buy rating on the stock.

QUALCOMM Incorporated (NASDAQ:QCOM): Susquehanna said their near term confidence continues to build in the handset related names such as Qualcomm) and Maxim Integrated (NASDAQ:MXIM) after a recent Asia trip. The firm is convinced that the semi-stocks have come to a cyclical trough but handsets continue to be the exception and see upside in the group. Both Qualcomm and Maxim have been given Positive ratings.

Don’t Miss: Here’s How China is Cheering Up Apple.